These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 24812287)
1. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF Ann Rheum Dis; 2015 Jun; 74(6):1102-9. PubMed ID: 24812287 [TBL] [Abstract][Full Text] [Related]
2. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691 [TBL] [Abstract][Full Text] [Related]
3. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080 [TBL] [Abstract][Full Text] [Related]
4. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. Hambardzumyan K; Bolce RJ; Saevarsdottir S; Forslind K; Wallman JK; Cruickshank SE; Sasso EH; Chernoff D; van Vollenhoven RF RMD Open; 2016; 2(1):e000197. PubMed ID: 26958364 [TBL] [Abstract][Full Text] [Related]
5. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570 [TBL] [Abstract][Full Text] [Related]
6. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871 [TBL] [Abstract][Full Text] [Related]
7. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Saevarsdottir S; Rezaei H; Geborek P; Petersson I; Ernestam S; Albertsson K; Forslind K; van Vollenhoven RF; Ann Rheum Dis; 2015 Aug; 74(8):1509-14. PubMed ID: 24706006 [TBL] [Abstract][Full Text] [Related]
8. Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Curtis JR; Weinblatt ME; Shadick NA; Brahe CH; Østergaard M; Hetland ML; Saevarsdottir S; Horton M; Mabey B; Flake DD; Ben-Shachar R; Sasso EH; Huizinga TW Arthritis Res Ther; 2021 Jan; 23(1):1. PubMed ID: 33397438 [TBL] [Abstract][Full Text] [Related]
9. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827 [TBL] [Abstract][Full Text] [Related]
10. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918 [TBL] [Abstract][Full Text] [Related]
11. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370 [TBL] [Abstract][Full Text] [Related]
12. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Bakker MF; Cavet G; Jacobs JW; Bijlsma JW; Haney DJ; Shen Y; Hesterberg LK; Smith DR; Centola M; van Roon JA; Lafeber FP; Welsing PM Ann Rheum Dis; 2012 Oct; 71(10):1692-7. PubMed ID: 22596166 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. van der Helm-van Mil AH; Knevel R; Cavet G; Huizinga TW; Haney DJ Rheumatology (Oxford); 2013 May; 52(5):839-46. PubMed ID: 23287359 [TBL] [Abstract][Full Text] [Related]
14. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789 [TBL] [Abstract][Full Text] [Related]
15. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Curtis JR; Brahe CH; Østergaard M; Lund Hetland M; Hambardzumyan K; Saevarsdottir S; Wang X; Flake Ii DD; Sasso EH; Huizinga TW Curr Med Res Opin; 2019 Sep; 35(9):1483-1493. PubMed ID: 30777458 [No Abstract] [Full Text] [Related]
16. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894 [TBL] [Abstract][Full Text] [Related]
17. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711 [TBL] [Abstract][Full Text] [Related]
18. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604 [TBL] [Abstract][Full Text] [Related]
19. Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. Hambardzumyan K; Bolce RJ; Wallman JK; van Vollenhoven RF; Saevarsdottir S J Rheumatol; 2019 Jun; 46(6):555-563. PubMed ID: 30709958 [TBL] [Abstract][Full Text] [Related]
20. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. Luedders BA; Johnson TM; Sayles H; Thiele GM; Mikuls TR; O'Dell JR; England BR Semin Arthritis Rheum; 2020 Oct; 50(5):1058-1063. PubMed ID: 32911284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]